Spots Global Cancer Trial Database for acral melanoma
Every month we try and update this database with for acral melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | NCT04119024 | Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S... | Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi... | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | NCT05789043 | Acral Melanoma | camrelizumab+ap... camrelizumab+ap... camrelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | NCT00700882 | Melanoma (Skin) | dasatinib | 18 Years - | Eastern Cooperative Oncology Group | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | NCT04331093 | Acral Melanoma | SHR-1210+Apatin... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | NCT05789043 | Acral Melanoma | camrelizumab+ap... camrelizumab+ap... camrelizumab | 18 Years - | Peking University Cancer Hospital & Institute | |
| Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | NCT00788775 | Mucosal Lentigi... Acral Melanoma Melanoma | Nilotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | NCT05628883 | Metastatic Mela... Unresectable Me... Acral Melanoma Mucosal Melanom... Cutaneous Melan... Ocular Melanoma Uveal Melanoma Iris Melanoma Conjunctival Me... Non-Cutaneous M... | TBio-4101 Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
